INTRODUCTION
============

Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disorder that primarily affects motor neurons in the cerebral cortex, brainstem, and spinal cord (SC). Mounting evidence suggests that it is a complex multisystem neurodegenerative disorder with considerable phenotypic heterogeneity and widespread central nervous system (CNS) involvement ([@nlz142-B1]). Approximately 90% of ALS cases arise spontaneously, while the remaining 10% show predominantly autosomal dominant inheritance. Since the discovery of mutations in the Cu^2+^/Zn^2+^ superoxide dismutase (SOD1) gene and the C9orf72 mutation (each of which is responsible for 20% and 30%, respectively, of the familial ALS cases \[[@nlz142-B4], [@nlz142-B5]\]), a broad range of both causative and disease modifying gene variants have been associated with both sporadic and familial forms of ALS (reviewed in \[[@nlz142-B3], [@nlz142-B6]\]). This wide range of genetic influences reflects the complexity of the disease involving heterogeneous converging mechanisms, including RNA processing and stability, proteostasis impairment, mitochondrial dysfunction, increased oxidative stress, and neuroinflammation ([@nlz142-B7]). Thus, combination therapies targeting more than one disease-related cellular pathway may be required for efficient control of the pathological cascade contributing to motor neuron degeneration ([@nlz142-B10], [@nlz142-B11]). An important challenge for new and existing therapies is the need to maintain therapeutic exposure in the brain and SC, which are protected by the blood-brain barrier (BBB). Beyond simply acting as a passive barrier, recent attention has been focused on BBB-driven drug-resistance in ALS, mediated by the ATP-binding cassette (ABC) drug efflux transporters (\[[@nlz142-B12]\]; for reviews see \[[@nlz142-B13], [@nlz142-B14]\]).

Several studies provide evidence of impairment of blood-brain and blood-spinal cord barrier function at an early stage in both patients and animal models of ALS (for reviews see \[[@nlz142-B14], [@nlz142-B15]\]). The compensatory overexpression of ABC efflux transporter proteins P-glycoprotein (P-gp)/ABCB1 and breast cancer resistance protein (BCRP)/ABCG2 that protect affected tissues by pumping foreign substances and drugs out is a common feature of diseases associated with multidrug resistance ([@nlz142-B16]). Overexpression of P-gp in ALS mutant mice has been demonstrated, suggesting a possible contribution of these pumps toward drug resistance in ALS patients ([@nlz142-B12], [@nlz142-B19]). As an example of the importance of this mechanism, Jablonski et al showed improved effects of riluzole in SOD1 transgenic mice when administered in combination with the dual P-gp/BCRP inhibitor elacridar ([@nlz142-B21]). The hypothesis that ABC drug efflux transporters may impact CNS distribution of therapeutic agents in ALS patients is supported by the observation that expression of P-gp and BCRP was increased in SC extracts from 3 ALS patients ([@nlz142-B12]). However, the cellular distribution of P-gp and BCRP within the affected human motor cortex and SC was not shown and the cohort studied was very small.

The aim of this study is to investigate the expression patterns of 2 ABC efflux transporters, P-gp and BCRP in SC, motor cortex (MCx), and cerebellum from a large, genetically well-characterized cohort of patients with sporadic or familial forms of ALS.

MATERIALS AND METHODS
=====================

Subjects
--------

Postmortem material was obtained at autopsy from 25 ALS patients at the department of (Neuro)pathology of the Amsterdam UMC, Academic Medical Center, University of Amsterdam, the Netherlands. All patients fulfilled the diagnostic criteria for ALS (El Escorial criteria \[[@nlz142-B25]\]) as reviewed independently by 2 neuropathologists. All patients with ALS died from respiratory failure. Control SC tissue was obtained from 14 patients who had died from a nonneurological disease. ALS and control patients included in the study did not show any sign of infection before death. The ALS patients included in the study did not receive medications such as riluzole or edaravone that are substrates of P-gp and/or BCRP. Informed consent was obtained for the use of brain tissue and for access to medical records for research purposes and approval was obtained from the relevant local ethical committees for medical research. All autopsies were performed within 12 hours after death.

Tissue Preparation
------------------

Paraffin-embedded tissue was sectioned at 6 µm and mounted on precoated glass slides (StarFrost, Waldemar Knittel Glasbearbeitungs GmbH, Braunschweig, Germany). Representative sections of all specimens were processed for hematoxylin and eosin, Klüver-Barrera or Nissl staining. To define different cell populations serial sections were stained with Nissl, astroglial and microglial markers (glial fibrillary acidic protein \[GFAP\] and HLA-DR, see following paragraph).

Immunohistochemistry
--------------------

Sections were deparaffinated in xylene, rinsed in ethanol (100%, 96%, 70%) and incubated for 20 minutes in 0.3% hydrogen peroxide diluted in methanol. Antigen retrieval was performed using a pressure cooker in 0.01 M sodium citrate, pH 6.0 at 121°C for 10 minutes. Slides were washed with phosphate-buffered saline (pH 7.4) and incubated overnight with primary antibody. GFAP (polyclonal rabbit, DAKO, Glostrup, Denmark; 1:4000), vimentin (mouse clone V9, DAKO; 1:400), major histocompatibility complex class II antigen (HLA)-DP, DQ, DR (mouse clone CR3/43; DAKO; 1:400), or CD68 (mouse clone PG-M1, DAKO; 1:200) was used in the routine immunohistochemical analysis of ALS specimens. For the detection of P-gp we used a monoclonal mouse antibody (IgG1, JSB-1, 1:40; Abcam, Cambridge, UK) as well as for BCRP (IgG2a, BXP-21, 1:100; Abcam). Single-label immunohistochemistry was performed as previously described ([@nlz142-B26]) with the Brightvision kit (Immunologic, Duiven, the Netherlands) and Bright DAB (Immunologic) as the chromogen.

To determine whether P-gp and BCRP colocalized with endothelial cells and astrocytes, sections were first incubated with respectively CD34 (mouse clone QBEnd10; Immunotech, Marseille, France; 1:600) or GFAP (polyclonal rabbit, DAKO; 1:4000) for 1 hour at room temperature, followed by staining using the Powervision kit (Immunologic) and 3-amino-9-ethylcarbazole (\[AEC\], Sigma-Aldrich, Zwijndrecht, the Netherlands) as a chromogen. Next, CD34 and GFAP antibodies were removed by incubating the sections at 121°C in 0.01 M citrate buffer (pH 6.0) for 10 minutes. Sections were then incubated for 1 hour at room temperature with the second primary antibody (P-gp, IgG1, JSB-1, 1:40, Abcam, or BCRP, IgG2a, BXP-21, 1:100, Abcam) and stained with a polymer-alkaline phosphatase (AP)-labeled antimouse antibody (Immunologic) and Vector Blue (AP Substrate Kit III, \#SK-5300, Vector Labs, Burlingame, CA) as a chromogen. For spectral analysis ([Supplementary Data Figs. S4 and S5](#sup1){ref-type="supplementary-material"}), images were analyzed with a Nuance VIS-FL Multi-spectral Imaging System (Cambridge Research Instrumentation, Woburn, MA), as described previously ([@nlz142-B27], [@nlz142-B28]).

In addition to spectral analysis as described in the previous paragraph, double-labeling of P-gp (IgG1, JSB-1, 1:40; Abcam) or BCRP (IgG2a, BXP-21, 1:100; Abcam) with GFAP (polyclonal rabbit, DAKO, Glostrup, Denmark; 1:4000) was performed using immunofluorescence ([Supplementary Data Fig. S6](#sup1){ref-type="supplementary-material"}). Sections were incubated overnight at 4°C with primary antibodies, followed by incubation with secondary antibody Alexa Fluor 568-conjugated antirabbit and Alexa Fluor-conjugated 488 antimouse IgG (1:100, Thermo Fisher Scientific, Landsmeer, the Netherlands) for 2 hours at room temperature. Sections were then analyzed using a laser scanning confocal microscope (Leica TCS Sp2, Amsterdam, the Netherlands).

Evaluation of Immunostaining
----------------------------

All labeled tissue sections were evaluated for the presence or absence of various histopathological parameters and specific immunoreactivity (IR) for the different markers. P-gp and BCRP IR was evaluated in microvessels (with size below 100 µm) and glial cells in both SC and motor cortex. The intensity of P-gp and BCRP-immunoreactive staining was evaluated using a scale of 0--3 (0: no; 1: weak; 2: moderate; 3: strong IR). See [Supplementary Data Figure S3](#sup1){ref-type="supplementary-material"} for typical examples of staining in blood vessels. The approximate proportion of cells showing IR \[(i) single to 10%; (ii) 11%--50%; (iii) \>50%\] was also scored to give information about the relative number of positive cells within the ALS specimens. As previously reported ([@nlz142-B26]), the product of these 2 values (intensity and relative number scores) gave the total score (IR score).

Western Blot
------------

Tissue samples of the motor cortex and SC (control n = 6, sporadic \[sALS\] n = 6, and familial \[fALS\], n = 5) were homogenized in lysis buffer (20 mM TRIS-HCl \[pH 8\], 137 mM NaCl, 1 mM Na~3~VO~4~, 8% glycerol, 1% triton X-100, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 µg/mL leupeptin, 10 µg/mL aprotinin, 10 µg/mL typsin inhibitor). Next, they were centrifuged for 15 minutes at 18 000*g*. Protein content was determined using the Bio-Rad (Hercules, CA) DC protein assay kit. Per sample, 40 µg of proteins was loaded on a NuPAGE 4%--12% Bis-Tris Midi protein gels, 26-well (Thermo Fisher Scientific, Waltham, MA) and electrophoreses was performed for 2 hours at 30 mA. The temperature of the running buffer (MOPS buffer \[Invitrogen, Carlsbad, CA\] 1:20) was maintained below 10°C. Gels were dry-blotted on nitrocellulose and these were probed for P-gp with MDR1/ABCB1(E1Y7S) rabbit mAb \#13978 1:1000 (Cell Signaling Technologies, Leiden, the Netherlands) or for BCRP with BXP-53 1:400 (ab24115; Abcam). Secondary HRP-antirabbit or HRP antirat 1:2000 (both from DAKO, Santa Clara, CA), respectively, were used and the blot exposed to ECL reagent (35 µg/mL coumaric acid, 220 µg/mL luminol, 0.0075% H~2~O~2~ in 100 mM TRIS pH 8.5) and images were taken on a Chemidoc XRS+ (Bio-Rad) and analyzed using Image Lab software (v5.2.1).

Statistical Analysis
--------------------

Statistical analyses were performed using the GraphPad Prism software (GraphPad software Inc., La Jolla, CA). Data were analyzed with the nonparametric Kruskal-Wallis test, followed by a Dunn's post hoc test to assess the difference between groups. A p value \< .05 was considered to indicate a significant difference.

RESULTS
=======

Case Material
-------------

The clinical and neuropathological characteristics of the subjects are summarized in [Table 1](#nlz142-T1){ref-type="table"}. The cohort included 17 sALS and 8 fALS patients, patients with rapid disease progression and short-term survival (\<18 months; ALS-st; n = 6) and patients with slow disease progression and long-term survival \>40 months (ALS-lt; n = 7). Six patients (5 fALS, 1 sALS) were positive for the C9ORF72 hexanucleotide repeat expansion. Mutations in FUS (fused in sarcoma/translocated in liposarcoma) were detected in 3 patients. There were no significant differences between the ALS and normal control groups with respect to postmortem interval or duration of tissue storage. None of the control patients had confounding neurological or neuropathological abnormalities.

###### 

Clinical Data of Cases

  Patients    Clinical Diagnosis   Gender   Site of Onset   Age (Years)   Disease Duration (Months)   C9orf72 Repeat Expansion FUS mutation
  ---------- -------------------- -------- --------------- ------------- --------------------------- ---------------------------------------
  1                  sALS            M         Bulbar           75                   28                                --
  2                  sALS            F        Spinal^1^         61                   27                                --
  3                  sALS            M        Spinal^1^         60                   12                                --
  4                  sALS            F        Spinal^1^         61                   12                                --
  5                  sALS            F        Spinal^2^         56                   16                                --
  6                  sALS            M        Spinal^2^         75                   19                                --
  7                  sALS            F         Bulbar           65                   52                                --
  8                  sALS            M        Spinal^1^         50                   56                                --
  9                  sALS            F         Bulbar           61                   43                                --
  10                 sALS            M        Spinal^2^         59                   45                                FUS
  11                 sALS            F        Spinal^2^         65                   25                                --
  12                 sALS            M         Bulbar           53                   31                              C9orf72
  13                 sALS            F        Spinal^1^         56                    7                                --
  14                 sALS            F         Bulbar           35                   20                                FUS
  15                 sALS            F           Arm            70                   24                                FUS
  16                 sALS            F           Arm            39                   130                               --
  17                 sALS            M         Bulbar           58                   14                                --
  18                 fALS            F         Bulbar           37                   26                                --
  19                 fALS            M        Spinal^2^         52                   43                                --
  20                 fALS            F        Spinal^2^         64                   57                              C9orf72
  21                 fALS            M        Spinal^2^         68                   33                              C9orf72
  22                 fALS            M        Spinal^2^         51                   23                              C9orf72
  23                 fALS            F        Spinal^1^         41                   16                                --
  24                 fALS            M        Spinal^1^         61                   33                              C9orf72
  25                 fALS            F         Bulbar           66                   34                              C9orf72
  1                Control           M           n/a            54                   n/a                               n/a
  2                Control           M           n/a            56                   n/a                               n/a
  3                Control           F           n/a            66                   n/a                               n/a
  4                Control           F           n/a            73                   n/a                               n/a
  5                Control           F           n/a            63                   n/a                               n/a
  6                Control           M           n/a            65                   n/a                               n/a
  7                Control           M           n/a            49                   n/a                               n/a
  8                Control           F           n/a            44                   n/a                               n/a
  9                Control           M           n/a            75                   n/a                               n/a
  10               Control           M           n/a            48                   n/a                               n/a
  11               Control           F           n/a            66                   n/a                               n/a
  12               Control           F           n/a            45                   n/a                               n/a
  13               Control           M           n/a            47                   n/a                               n/a
  14               Control           M           n/a            63                   n/a                               n/a

Site of onset (region in which first symptoms occurred): Bulbar onset, spinal onset (upper 1, lower 2). Age: years. Disease duration: time from diagnosis until death in months. The ALS patients included in the study did not receive medications such as riluzole or edaravone that are substrates of P-gp and/or BCRP. Fused in sarcoma/translocated in liposarcoma (FUS), chromosome 9 open reading frame 72 (C9orf72). sALS cases without C9ORF72 hexanucleotide repeat expansion or mutations were analyzed by targeted NGS analysis. The NGS panel consists of TARBP, ALS2, ErbB4, NEK1, MATR3, VCP, SIGMAR1, c9orf72, c19orf12, OPTN, HNRNPA1, DAO, SPG11, FUS, GRN, PNPLA6, SOD1, CHCHD10, NEFH, and UBQLN2.

ALS, amyotrophic lateral sclerosis; sALS, sporadic ALS; fALS, familial ALS; M, male; F, female, n/a, not applicable.

P-gp and BCRP Cellular Distribution in ALS SC and Motor Cortex
--------------------------------------------------------------

[Figure 1](#nlz142-F1){ref-type="fig"} shows P-gp protein expression in a representative normal and ALS cervical SC white matter (\[WM\] lateral corticospinal tract) and ventral horn (VH). P-gp expression was observed in endothelial cells lining the blood vessels in both control and ALS specimens ([Fig. 1](#nlz142-F1){ref-type="fig"}; quantification see [Fig. 3A](#nlz142-F3){ref-type="fig"}). In controls, P-gp could not be detected in the large majority of glial cells with resting morphology ([Figs. 1A and 3B](#nlz142-F1){ref-type="fig"}). In all ALS cases, P-gp IR was evident in cells with typical glial morphology ([Figs. 1E--G](#nlz142-F1){ref-type="fig"} and [3B](#nlz142-F3){ref-type="fig"}). A similar cellular distribution was observed in the MCx with strong expression of P-gp in blood vessels in both controls and ALS cases and higher expression in reactive astrocytes in both gray and white matter ([Figs. 2](#nlz142-F2){ref-type="fig"} and [3C, D](#nlz142-F3){ref-type="fig"}). Double labeling demonstrated P-gp expression in endothelial cells (CD34-positive cells; [Figs. 1H--I](#nlz142-F1){ref-type="fig"} and [2I](#nlz142-F2){ref-type="fig"}, [Supplementary Data Fig. S4A](#sup1){ref-type="supplementary-material"} \[spectral analysis\]) and reactive astrocytes (GFAP-positive cells; [Figs. 1F, G](#nlz142-F1){ref-type="fig"} and [2H](#nlz142-F2){ref-type="fig"}, [Supplementary Data Fig. S4B](#sup1){ref-type="supplementary-material"} \[spectral analysis\] and [Supplementary Data Fig. S6A](#sup1){ref-type="supplementary-material"} \[fluorescent double labeling\]), but not in cells of the microglial/macrophage lineage (HLA-DR-positive cells; [Figs. 1J and 2J](#nlz142-F1){ref-type="fig"}). In cerebellum, P-gp expression was observed in blood vessels, but could not be detected in the majority of glial cells ([Supplementary Data Fig. S1A, B](#sup1){ref-type="supplementary-material"}).

![P-gp immunoreactivity in control and ALS spinal cord. **(A, B)** Representative photomicrographs of immunohistochemical staining for P-gp in control spinal cord (SC) (white matter \[WM\], lateral corticospinal tract; **A**; ventral horn \[VH\]; **B**; asterisk: negative motoneuron) showing expression in blood vessels (arrows), but no detectable immunoreactivity in the majority of glial cells (inset in **A**). **(C--G)** Representative photomicrographs of immunohistochemical staining for P-gp in ALS SC. In ALS SC immunoreactivity was observed in blood vessels (arrows in **C--E**) and reactive astrocytes in (arrowheads in **C, E**). **(F, G)** Colocalization (purple; arrows) of GFAP (red) and P-gp (blue) in reactive astrocytes (surrounding P-gp-positive vessels in **G**). **(H, I)** Colocalization (purple; arrows) of CD34 (red) and P-gp (blue) in blood vessels. **(J)** Absence of expression of P-gp (blue; arrow indicates a positive blood vessel) in cells of the microglial/macrophage lineage (arrows indicate HLA-DR-positive cells; red). Scale bars: **A--D** = 40 μm; **E, G** = 25 μm; **F, H--J **= 15 μm.](nlz142f1){#nlz142-F1}

![P-gp immunoreactivity in control and ALS motor cortex. **(A--C)** Representative photomicrographs of immunohistochemical staining for P-gp in control motor cortex (MCx; **A**, white matter \[WM\]; **B**, gray matter \[GM\]) showing expression in blood vessels (arrows), but in the majority of glial cells P-gp could not be detected. **(C--G)** Representative photomicrographs of immunohistochemical staining for P-gp in ALS MCx. P-gp immunoreactivity was detected in blood vessels (arrows). A substantial increase in immunoreactivity was observed in ALS motor cortex with numerous glial cells (arrowheads in **D, E, G**). **(H)** Colocalization (purple; arrow) of GFAP (red) and P-gp (blue) in reactive astrocytes (surrounding a P-gp-positive vessel). **(I)** Colocalization (purple; arrow) of CD34 (red) and P-gp (blue) in a blood vessel. **(J)** Absence of expression of P-gp (blue; arrow indicates a positive blood vessel) in cells of the microglial/macrophage lineage (arrow indicate an HLA-DR-positive cell; red). Scale bars: **A--F **=** **40 μm; **G--J **=** **15 μm.](nlz142f2){#nlz142-F2}

![P-gp immunoreactivity scores in control and ALS spinal cord and motor cortex. Plots showing P-gp mean immunoreactivity score (IRS) in blood vessels (microvessels, size \<100 µm) and glial cells (astrocytes) in control (n = 14) and ALS cases (n = 25). The IRS represents the mean total score, which was taken as the product of the intensity score and the relative number score (for details see Materials and Methods section).](nlz142f3){#nlz142-F3}

[Figure 4](#nlz142-F4){ref-type="fig"} shows BCRP protein expression in a representative normal and ALS cervical SC (VH and WM; [Fig. 4A--D](#nlz142-F4){ref-type="fig"}) and the MCx ([Fig. 4E--J](#nlz142-F4){ref-type="fig"}). BCRP expression was mainly observed in endothelial cells lining the blood vessels in both control and ALS specimens ([Fig. 4](#nlz142-F4){ref-type="fig"}). Expression of BCRP in blood vessels did not differ between control and ALS in both the both VH and WM; a modest increase of the IR score was detected for BCRP in the MCx of ALS patients ([Fig. 5E](#nlz142-F5){ref-type="fig"}). Resting glial cells did not express detectable levels of BCRP; occasionally in ALS reactive astrocytes showed BCRP expression ([Figs. 4G](#nlz142-F4){ref-type="fig"} and [5B, D](#nlz142-F5){ref-type="fig"}). BCRP expression in blood vessels was also detected in cerebellum of both controls and ALS. ([Supplementary Data Fig. S1C, D](#sup1){ref-type="supplementary-material"}). Double labeling demonstrated BCRP expression in endothelial cells (CD34-positive cells; [Fig. 4J](#nlz142-F4){ref-type="fig"} and [Supplementary Data Fig. S5A](#sup1){ref-type="supplementary-material"}) and reactive astrocytes (GFAP-positive cells; [Fig. 4I](#nlz142-F4){ref-type="fig"} and [Supplementary Data Fig. S5B](#sup1){ref-type="supplementary-material"} \[spectral analysis\] and [Supplementary Data Fig. S6B](#sup1){ref-type="supplementary-material"} \[fluorescent double labeling\]), but not in cells of the microglial/macrophage lineage (not shown).

![BCRP immunoreactivity in control and ALS spinal cord and motor cortex. **(A, B)** Representative photomicrographs of immunohistochemical staining for BCRP in control spinal cord (SC) (white matter \[WM\], lateral corticospinal tract; **A**; ventral horn, **B**; asterisk shows a negative motoneuron), showing expression in blood vessels (arrows). **(C, D)** Representative photomicrographs of immunohistochemical staining for BCRP in ALS SC showing expression in blood vessels (arrows). **(E, F)** Representative photomicrographs of immunohistochemical staining for BCRP in control motor cortex (MCx; **E**, WM; **F**, gray matter, \[GM\]) showing weak to moderate expression in blood vessels (arrows). **(G, H)** Representative photomicrographs of immunohistochemical staining for BCRP in ALS motor cortex. BCRP immunoreactivity was detected in blood vessels (arrows); occasionally a few positive glial cells were observed (arrowheads in **G**; around a positive blood vessel, inset in **G**). **(I)** Colocalization (purple; arrowhead) of GFAP (red) and BCRP (blue) in reactive astrocytes (surrounding a BCRP-positive vessel). **(J)** Colocalization (purple; arrow) of CD34 (red) and BCRP (blue) in a blood vessel. Scale bars: **A--H **=** **40 μm; **G--J **=** **20 μm.](nlz142f4){#nlz142-F4}

![BCRP immunoreactivity scores in control and ALS spinal cord and motor cortex. Plots showing BCRP mean immunoreactivity score (IRS) in blood vessels (microvessels, size \<100 µm) and glial cells (astrocytes) in control (n = 14) and ALS (n = 25) cases. The IRS represents the mean total score, which was taken as the product of the intensity score and the relative number score (see Materials and Methods section for details).](nlz142f5){#nlz142-F5}

P-gp and BCRP glial and blood vessel IR differed neither between sALS and fALS cases in both the SC and MCx nor between patients with and without C9ORF72 hexanucleotide repeat expansion. P-gp glial expression was markedly higher compared with controls in ALS-lt, although not significantly different compared with patients with ALS-st ([Supplementary Data Fig. S2](#sup1){ref-type="supplementary-material"}).

Western blot analysis did not show differences in P-gp and BCRP expression in the motor cortex and SC between control, fALS and sALS (data not shown).

DISCUSSION
==========

In this study, we used immunohistochemistry to compare and semiquantitatively assess ABC transporter expression at the BBB and in brain parenchyma in postmortem brain and SC tissues of 25 ALS patients versus 11 controls. We demonstrate that P-gp expression in endothelial cells at the BBB is maintained, while a significant and strongly increased P-gp expression is observed in reactive astroglial cells in both gray (VH) and white matter of the SC, as well as in the MCx of all ALS patients, but not in cerebellum. BCRP expression was moderately but significantly increased in glia and blood vessels in the MCx of ALS patients. P-gp or BCRP IR did not differ between sALS and fALS cases. This higher expression is in line with results from a previous study in a small set of patients ([@nlz142-B12]). In contrast to the immunohistochemical findings, we could not detect differences in P-gp or BCRP expression between groups using Western blot analysis. This can most likely be explained by the fact that tissue homogenates are used for Western blot, which is not particularly suitable to discern relatively small differences in expression at the cellular level.

BBB impairment is an early event in the pathogenesis of patients with ALS ([@nlz142-B15]) as in other neurodegenerative diseases ([@nlz142-B29], [@nlz142-B30]). Also, in the SOD1 mouse model for ALS, increased permeability of the BBB was an early symptom that occurred prior to motor neuron loss ([@nlz142-B31]). Perturbation of tight junctions increases the leakiness of the BBB as shown in ALS ([@nlz142-B31]) and other neurodegenerative disorders ([@nlz142-B32]). While entry of potentially neurotoxic macromolecules such as hemoglobin and albumin through a more permeable BBB may be an underlying cause of ALS, a higher permeability could potentially facilitate the entry of therapeutics into diseased CNS tissues. On the other hand, however, upregulation of the drug efflux pumps P-gp and BCRP, as seen in this study in ALS patients and in patients with HIV encephalitis ([@nlz142-B36]), multiple sclerosis ([@nlz142-B37]) and glioblastoma ([@nlz142-B31]), may result in an attenuation of the efficacy of therapeutics. In SOD1-G93A and TDP-43 rodent models, disease progression correlated with a selective upregulation of P-gp and BCRP, both at the mRNA and protein level, in homogenized SC tissues ([@nlz142-B12], [@nlz142-B19], [@nlz142-B24], [@nlz142-B38]). Concomitant administration of the dual P-gp/BCRP inhibitor elacridar improved the efficacy of riluzole in SOD1-G93A ALS mice, indicating that pharmaco-resistance is at least partially mediated by drug efflux transporters ([@nlz142-B12], [@nlz142-B21]).

P-gp (encoded by ABCB1) and BCRP (encoded by ABCG2) unidirectional efflux pumps are widely distributed in the body, with high expression at the BBB, the intestines, liver and in stem cells ([@nlz142-B39], [@nlz142-B40]). BCRP and P-gp have broad and overlapping substrate specificities, including many known drugs, and they function redundantly or synergistically in removing substrate drugs from pump-protected cells and tissues, causing multidrug resistance ([@nlz142-B40]). Comparisons of wildtype versus ABC-transporter knockout mice demonstrate that absence of both P-gp and BCRP caused a redistribution of substrate drugs from peripheral tissues into pump-protected "sanctuary tissues," such as the brain without affecting plasma levels ([@nlz142-B40], [@nlz142-B41], [@nlz142-B46]).

Clinical studies in ALS patients demonstrated that riluzole is effective and even showed disease-modifying activity in early stage, but this benefit was transient and lost in late stage ([@nlz142-B50]). In 155 ALS patients, mortality was reduced by 38% during the first 12 months of treatment and this benefit was reduced to 19% at 21 months ([@nlz142-B51]). Edaravone, which is the only other approved drug for treatment of ALS, also demonstrated efficacy (i.e. reduced functional decline or ALSFRS-R score) but also only in a subset of patients with early stage ALS ([@nlz142-B52]). Several other agents that demonstrated benefit in preclinical models failed to show efficacy in clinical trials ([@nlz142-B53]) ([Table 2](#nlz142-T2){ref-type="table"}). Although lack of efficacy may have various roots, this may include suboptimal drug exposure due to insufficient BBB penetration. In fact, approximately 98% of all FDA-approved small molecule drugs do not maintain effective exposure in the brain often also due to the action of P-gp and/or BCRP ([@nlz142-B54]). Consequently, adequate penetration of the BBB by any novel candidate therapeutic remains an important consideration when testing a novel therapy. Dual inhibitors of P-gp and BCRP, such as elacridar, may help to improve therapy ([@nlz142-B12], [@nlz142-B21]). Moreover, in our study we observed an increased expression, particularly of P-gp in astrocytes within the affected brain regions in both sALS and fALS cases. Accordingly, increased expression of ABC-transporters in perivascular and parenchymal astrocytes has also been reported in various pharmaco-resistant neurological disorders ([@nlz142-B18]). Astrocytes represent a key component of the neurovascular unit and several studies highlight the role of astrocytes in maintaining P-gp expression in BBB-endothelial cells, thereby restricting the penetration of xenobiotics into the CNS ([@nlz142-B57]). Interestingly, apart from removal of xenobiotics, P-gp in astrocytes may act as modulator of the immune response regulating the secretion of inflammatory molecules ([@nlz142-B36], [@nlz142-B58]), and several studies indicate a complex regulation of their astroglial expression by pro-inflammatory pathways ([@nlz142-B18]). Recently, it has also been shown that astrocytes harboring ALS causative mutations (i.e. FUS and SOD1m, but not C9orf72) drive P-gp upregulation in endothelial cells through soluble factors, including inflammatory molecules, as well as glutamate ([@nlz142-B14], [@nlz142-B59]).

###### 

FDA-Approved Drugs With Strong Preclinical Data, Failed in ALS Clinical Trials

  ALS status     Drug               References P-gp/BCRP Substrate
  -------------- ------------------ --------------------------------------------------------------
  FDA approved   Riluzole           ([@nlz142-B20], [@nlz142-B21], [@nlz142-B61], [@nlz142-B62])
                 Edaravone IV       ([@nlz142-B63])
  Not approved   Masitinib          ([@nlz142-B64])
                 Cyclosporin        ([@nlz142-B65], [@nlz142-B66])
                 Ceftriaxone        ([@nlz142-B67])
                 Celecoxib          ([@nlz142-B68], [@nlz142-B69])
                 (Dex)pramipexole   ([@nlz142-B70])
                 Gabapentin         ([@nlz142-B71], [@nlz142-B72])
                 Minocycline        ([@nlz142-B20])
                 rHCNTF             ([@nlz142-B73])
                 Topiramate         ([@nlz142-B72], [@nlz142-B74])
                 Vitamin E          ([@nlz142-B75], [@nlz142-B76])
  Candidate      Raltegravir        ([@nlz142-B44], [@nlz142-B77])
                 Imatinib           ([@nlz142-B78])

In conclusion, our results show high expression of P-gp and BCRP at the blood-brain and SC barrier in healthy controls and ALS patients. In addition, in ALS patients we observed a strong upregulation of P-gp in astrocytes in both the SC and MCx, whereas BCRP showed a moderate increase in glial cells and blood vessels in cortex. The ALS patients included in the study did not receive medications such as riluzole or edaravone that are substrates of P-gp and/or BCRP. However, the use of drugs which induce ABC-transporters could represent a contributing factor leading to the ABC-transporter-mediated multidrug resistance in ALS patients ([@nlz142-B60]). The high expression of both drug efflux pumps may thwart the efficacy of approved substrate drugs (riluzole, edaravone) and obstruct the successful employment of other novel candidate agents. ALS is a debilitating and deadly disease with very few therapeutic options. Besides the obvious need of identifying appropriate targets and targeted therapeutics for better therapy, this ABC-transporter-mediated multidrug resistance calls for effective strategies to ensure adequate BBB-crossing and therapeutic drug exposure.
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